Labcorp (NYSE:LH) EVP Kathryn Kyle Sells 762 Shares of Stock

Labcorp Holdings Inc. (NYSE:LH) EVP Kathryn Kyle sold 762 shares of Labcorp stock in a transaction on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the transaction, the executive vice president owned 3,813 shares in the company, valued at $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Price Performance

NYSE LH opened at $268.52 on Thursday. The company has a market capitalization of $22.02 billion, a PE ratio of 23.78, a price-to-earnings-growth ratio of 1.90 and a beta of 0.90. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The business’s fifty day moving average is $262.84 and its 200 day moving average is $265.78. Labcorp Holdings Inc. has a fifty-two week low of $241.81 and a fifty-two week high of $293.72.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 18 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s payout ratio is 25.51%.

Hedge Funds Weigh In On Labcorp

Several large investors have recently made changes to their positions in LH. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp in the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp in the fourth quarter worth about $27,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the third quarter worth about $28,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp in the fourth quarter worth about $29,000. Finally, DV Equities LLC bought a new stake in shares of Labcorp in the fourth quarter worth about $29,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LH. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Robert W. Baird set a $334.00 price objective on Labcorp in a research report on Friday, May 1st. JPMorgan Chase & Co. boosted their price objective on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Piper Sandler boosted their price objective on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.